2020 has not only borne witness to a global pandemic, but also to increasing fervor in the fight for racial equity. In a wave of opposition to the systemic racism in the U.S., people have been in the streets demonstrating and protesting against social injustice and have taken to social media to promote political action….
Our hospitals have had their finest hour in the care of acutely ill inpatients during the COVID-19 pandemic, including dealing with allocation decisions fairly and transparently, maximizing good outcomes and remaining cognizant of the enduring ethics of healthcare. The honorable traditions of self-effacing conduct and acceptance of some level of personal risk by healthcare professionals…
2020 marks an important milestone for the Rheumatology Research Foundation. It is the Foundation’s 35th anniversary—a time when we can reflect on our past triumphs and look forward to a bright future for our profession and for our patients. The ACR established the Research and Education Foundation, later renamed the Rheumatology Research Foundation, in 1985,…
On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics. I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting. This group of scientists met to discuss all that was still…
Ironically, chronic exposure to minocycline has also been associated with a variety of autoimmune syndromes, including drug-induced lupus, autoimmune hepatitis, serum sickness and vasculitis.1 Minocycline is associated with an 8.5-fold increased risk of drug-induced lupus.2 Minocycline and nitrofurantoin are implicated in 90% of cases of drug-induced autoimmune hepatitis.3 Minocycline-induced vasculitis is much less common and,…
Rep. Kim Schofield’s path to the Georgia House of Representatives started with her lupus diagnosis 20 years ago.
As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.
The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis.
RheumPAC will once again conduct a matching campaign in November, coinciding with ACR Convergence 2020. During this time, all donations to RheumPAC will be amplified by leaders from the College, who will match various dollar amounts for each contribution. Additionally, many will donate a larger amount for first-time investors. Last year, matching funds contributed $91…
Attendees at the daylong workshop will learn about key evaluation and management code changes coming in 2021 that affect rheumatologists and rheumatology professionals.